PIPELINE-PAGE

CLINICAL FINDINGS

We carried out, through an independent research organization (CRO), a randomized double-blinded placebo-controlled study (DBPC) on individuals aged 50-70 years with mild cognitive impairment (MCI). MCI affects 6M Americans and has no treatment today. We have significant positive results that will be reported in the next few months.


ONGOING CLINICAL TRIALS

We have a broad clinical development program focused primarily on neurological diseases with associated cognitive deficits – including Alzheimer’s, Adult ADHD and Schizophrenia.

Our four Phase 2A equivalent clinical trials, carried out at major academic centers under the approval of their respective IRBs, are expected to complete in 2015-2016:

Neurocentria+pipeline+v2